Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF PINDOLOL ON ONSET OF ACTION OF PAROXETINE IN THE TREATMENT OF MAJOR DEPRESSION - INTERMEDIATE ANALYSIS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Autore:
BORDET R; THOMAS P; DUPUIS B;
Indirizzi:
CTR HOSP REG UNIV LILLE,SERV PHARMACOL HOSP,REPP F-59045 LILLE FRANCE CTR HOSP REG UNIV LILLE,UNITE EVALUAT F-59045 LILLE FRANCE
Titolo Testata:
The American journal of psychiatry
fascicolo: 10, volume: 155, anno: 1998,
pagine: 1346 - 1351
SICI:
0002-953X(1998)155:10<1346:EOPOOO>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; EXTRACELLULAR SEROTONIN; AUTORECEPTOR BLOCKADE; ANTIDEPRESSANT DRUGS; FLUOXETINE; INCREASE; DESENSITIZATION; MICRODIALYSIS; CITALOPRAM; BLOCKERS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
R. Bordet et al., "EFFECT OF PINDOLOL ON ONSET OF ACTION OF PAROXETINE IN THE TREATMENT OF MAJOR DEPRESSION - INTERMEDIATE ANALYSIS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL", The American journal of psychiatry, 155(10), 1998, pp. 1346-1351

Abstract

Objective: The purpose of this study was to investigate the effect ofpindolol to accelerate the onset of action of paroxetine in patients suffering from major depression. Method: Patients who met DSM-IV criteria for a nonpsychotic disorder, who had no previously treated episodeof major depression episode, and who had a score of at least 18 on the 17-item Hamilton Depression Rating Scale were randomly assigned, forthe first 21 days, to treatment with paroxetine (20 mg/day) and either pindolol (5 mg t.i.d.) or placebo. Patients were evaluated with the Hamilton depression scale, the Montgomery-Asberg Depression Rating Scale, and Global Clinical impression (CGI) on days 0 (baseline), 5, 10, 15, 21, 25, 31, 60, 120, and 180. Results: Intermediate analysis of the first month's results for the first 100 patients (pindolol, N=50; placebo, N=50) was performed. At day 10 there were more improved patients (defined as patients with a maximum score of 10 on the Hamilton depression scale) in the pindolol plus paroxetine group (N=24; 48%) than in the placebo plus paroxetine group (N=13; 26%). At day 5 there was nostatistically significant difference, and at day 15 and thereafter, the differences between the two groups disappeared. Hamilton depressionscale scores were significantly lower on days 5 and 10 for the pindolol plus paroxetine group (mean=15.7, SD=5.3, and mean=11.7, SD=6.4, respectively) than for the placebo plus paroxetine group (mean=19, SD=5.9, and mean=14.7, SD=6.8); this was also true for Montgomery-Asberg depression scale and CGI scores. Conclusions: The addition of pindolol to paroxetine treatment significantly accelerates the onset of therapeutic response in patients suffering from major depression. Nevertheless, the mechanism (pharmacodynamic or pharmacokinetic) of this beneficial effect remains unclear.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 22:17:44